Correlation Between Onxeo SA and Novo Nordisk

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Onxeo SA and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Onxeo SA and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Onxeo SA and Novo Nordisk AS, you can compare the effects of market volatilities on Onxeo SA and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Onxeo SA with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of Onxeo SA and Novo Nordisk.

Diversification Opportunities for Onxeo SA and Novo Nordisk

0.32
  Correlation Coefficient

Weak diversification

The 3 months correlation between Onxeo and Novo is 0.32. Overlapping area represents the amount of risk that can be diversified away by holding Onxeo SA and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and Onxeo SA is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Onxeo SA are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of Onxeo SA i.e., Onxeo SA and Novo Nordisk go up and down completely randomly.

Pair Corralation between Onxeo SA and Novo Nordisk

Assuming the 90 days horizon Onxeo SA is expected to under-perform the Novo Nordisk. In addition to that, Onxeo SA is 3.6 times more volatile than Novo Nordisk AS. It trades about 0.0 of its total potential returns per unit of risk. Novo Nordisk AS is currently generating about 0.06 per unit of volatility. If you would invest  9,740  in Novo Nordisk AS on September 22, 2024 and sell it today you would earn a total of  220.00  from holding Novo Nordisk AS or generate 2.26% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Onxeo SA  vs.  Novo Nordisk AS

 Performance 
       Timeline  
Onxeo SA 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Onxeo SA are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Onxeo SA reported solid returns over the last few months and may actually be approaching a breakup point.
Novo Nordisk AS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders.

Onxeo SA and Novo Nordisk Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Onxeo SA and Novo Nordisk

The main advantage of trading using opposite Onxeo SA and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Onxeo SA position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.
The idea behind Onxeo SA and Novo Nordisk AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Complementary Tools

Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes